Home
About Us
Scientific Platforms
- ADCs
- Publications
Team
News
Contact

Search

Search
- Search

Home
About Us
Scientific Platforms
- ADCs
- Publications
Team
News
Contact

Home » Uncategorized » Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health

Uncategorized

Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health

by Mbio2018|Published September 1, 2018

https://projectreporter.nih.gov/project_info_description.cfm?aid=9623199&icde=51409496&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC&pball=

Project Number: 1R43CA228746-01A1

Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER

Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates

Published March 23, 2022

Grant Award from the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences

Research grant to support the development of novel monoclonal antibody and antibody-drug conjugate programs for the treatment of cancer NEW YORK, NY, […]

Published December 19, 2023

Manhattan BioSolutions Named as an Awardee of Science in the City QuickFire Challenge

Published March 2, 2021

Manhattan BioSolutions Announces Positive Preclinical Data Validating its Novel Synthetic Microbial Therapeutic Platform

New York City, New York Feb 23, 2021 (Issuewire.com) – Manhattan BioSolutions, Inc, an emerging biotechnology company focused on the discovery of immunoregulatory therapies […]

Previous post Manhattan BioSolutions has won prestigious Johnson & Johnson Innovation QuickFire Challenge Competition and award to receive free laboratory and office space at the newly open JLabs@NYC incubator in downtown Manhattan
Back to post list
Next post Manhattan BioSolutions establishes new laboratory space at the JLabs JNJ Innovation incubator in New York City